Wyeth is unique in having discovery and development expertise in three distinct but complementary areas – pharmaceuticals, vaccines and biotechnology.
The programmes are currently focused on neurosciences, where novel treatments for conditions such as multiple sclerosis, Alzheimers Disease and schizophrenia are being investigated. Vaccines and infectious disease, musculoskeletal disorders, immunology and oncology, female health and haemophilia are also at the forefront of our research initiations.
In recent years, Wyeth has re-engineered its entire R&D process to ensure that programmes relate to high medical needs. The Company is now one of the top performers in drug discovery output and the aim is to bring two new products to the market each year.